Safety Study to Assess the Feasibility of Use in Humans of the TAXUS Petal Bifurcation Coronary Stent System

Cardiovascular Diseases Clinical Trial

Official title:

A Prospective, Single-arm, Multicenter 2-phase Feasibility Study to Assess the TAXUS Petal Paclitaxel-Eluting Bifurcation Coronary Stent System (TAXUS Petal)for the Treatment of de Novo Atherosclerotic Bifurcation Lesions

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00497367
• Other study ID #: S2030
• Secondary ID: S2030-FHU-2007
• Status: Completed
• Phase: Phase 1
• First received: July 4, 2007
• Last updated: March 25, 2015
• Start date: July 2007
• Est. completion date: June 2013

Study information

• Verified date: March 2015
• Source: Boston Scientific Corporation
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)Germany: Federal Institute for Drugs and Medical DevicesNew Zealand: Health and Disability Ethics Committees
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety and feasibility of use in humans of the TAXUS Petal Paclitaxel-Eluting Bifurcation Coronary Stent System in the treatment of de novo lesions in native coronary arteries involving a major side branch. The TAXUS® Petal™ is an investigational device with an indication of improving coronary artery luminal diameter while maintaining side branch access in subjects with symptomatic ischemic disease due to discrete atherosclerotic bifurcation lesions

Description:

To assess the safety and feasibility of use in humans of the TAXUS Petal Paclitaxel-Eluting Bifurcation Coronary Stent System (TAXUS® Petal™) for the treatment of de novo atherosclerotic bifurcation lesions (by visual estimate):

• Phase 1:

• Main branch: 3.0 to 3.5 mm RVD and lesion length ≤20 mm

• Side branch: 2.5 to 3.5 mm RVD and lesion length ≤14 mm

• Phase 2:

• Main branch: 3.0 to 3.5 mm RVD and lesion length ≤28 mm

• Side branch: 2.25 to 3.5 mm RVD and lesion length ≤14 mm

Bifurcation main branch (MB) lesion length will be measured from the proximal shoulder of the most proximal lesion to the distal shoulder of the most distal lesion. Bifurcation side branch (SB) lesion length will be measured from the proximal shoulder of the side branch (if the ostium is disease-free) or the side branch ostium (if the disease continues into the main branch) to the distal side branch shoulder of the most distal lesion. At follow-up, the entire stented region will be used to determine MLD and %DS.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 28
• Est. completion date: June 2013
• Est. primary completion date: July 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria - Phases 1 and 2

• Age is =18 years old and =80 years old

• Eligible for PCI

• Acceptable candidate for CABG

• Documented stable angina pectoris (CCS Classification 1, 2, 3, or 4) or unstable angina pectoris with documented ischemia (Braunwald Class IB-C, IIB-C, or IIIB-C), or documented silent ischemia

• LVEF known to be =40%

• Clinical angiographic success in non-target lesion (if a non-target lesion is treated)

• Subject (or legal guardian) understands the study requirements and procedures and provides written Informed Consent before any study tests or procedures are performed

• Subject willing to comply with follow-up evaluations

Exclusion Criteria - Phases 1 and 2

• Contraindication to ASA, or to Thienopyridine derivatives (e.g. Clopidogrel, Ticlopidine)

• High risk of bleeding

• Known hypersensitivity to paclitaxel

• Known allergy to stainless steel

• Known allergy to platinum

• Previous treatment of the target vessel with any anti-restenotic drug-coated or drug-eluting coronary stent

• Previous treatment of the target vessel with BMS within 9 months before index procedure

• Previous treatment of any non-target vessel with any anti-restenotic drug-coated or DES within 9 months before index procedure

• Previous treatment with intravascular brachytherapy in the target vessel

• Planned PCI or CABG post-index procedure

• Planned target vessel treatment with an unapproved device, directional or rotational coronary atherectomy, laser, cutting balloon, or transluminal extraction catheter

• Documented MI within 72 hours prior to index procedure

• CK > 2 x ULN + positive CK-MB OR

• CK > 2 x ULN + positive troponin OR

• If no CK-MB or troponin was drawn, patients are excluded with CK > 2xULN

• As per protocol definitions found in Appendix A:

• CVA within the past 6 months

• Cardiogenic shock

• Acute or chronic renal dysfunction

• Prior anaphylactic reaction to contrast agents

• Leukopenia

• Thrombocytopenia

• Thrombocytosis

• Active peptic ulcer or active GI bleeding

• Current treatment, or past-treatment within 12 months of the index procedure, with paclitaxel or other chemotherapeutic agents

• Anticipated treatment with paclitaxel or oral rapamycin within 9 months of index procedure

• Subject's (men and women) known intention to procreate within 9 months of index procedure

• Positive pregnancy test or nursing an infant within 7 days prior to index procedure

• Life expectancy of less than 24 months due to other medical conditions

• Co-morbid condition(s) that could limit subject's ability to comply with study follow-up or impact study scientific integrity

• Currently participating in another investigational drug or device clinical study

• Planned surgery at time of enrollment within the next 9 months after index procedure

Angiographic Inclusion Criteria - Phases 1 & 2

• Target Lesion (main and / or side branch):

• located in native coronary artery

• must be de novo

• main branch %DS is =50% and <100%

• is a bifurcation lesion with an angle =30º and =90º

• is enrolled after successful pre-dilatation of the target vessel

Angiographic Inclusion Criteria - Phase 1

• Main branch of target lesion located in parent branch of LAD or LCx or RCA

• Target lesion located in proximal or mid-section of vessel only (crux of RCA [distal RCA] is allowed)

• Main branch RVD =3.00 mm to =3.5 mm; lesion length =20 mm (to be covered by TAXUS® Petal™ stent and maximum of 1 additional TAXUS stent =12 mm in length)

• Side branch RVD =2.5 mm to =3.5 mm; lesion length =14 mm to be treated by maximum of 1 TAXUS stent =16 mm in length Angiographic Inclusion Criteria - Phase 2

• Main branch of target lesion located in parent branch of LAD or LCx or RCA without restrictions

• Main branch RVD =3.00 mm to =3.5 mm; lesion length =28 mm (to be covered by TAXUS® Petal™ stent and maximum of 1 additional TAXUS stent =20 mm in length)

• Side branch RVD =2.25 mm to =3.5 mm; lesion length =14 mm to be treated by maximum of 1 TAXUS stent =16 mm in length

Angiographic Exclusion Criteria - Phases 1 & 2

• Target lesion located in left main (protected or unprotected)

• Medina Classification 0.0.1

• Target lesion is restenotic

• Target lesion located in a SVG or mammary artery graft

• Target lesion accessed via SVG or mammary artery graft

• Target lesion is <5 mm from BMS

• Target lesion is <5 mm from second side branch vessel =1.5 mm in diameter

• Untreated lesions with =50% DS or thought to impair flow remaining in target vessel

• Target lesion and/or vessel proximal to target lesion moderately or severely calcified

• Target lesion and/or target vessel proximal to target lesion severely tortuous

• Main branch target lesion located within or distal to a >60° bend in target vessel

• Target vessel with angiographic presence of probable or definite thrombus

• Unprotected LM disease

• Protected LM disease with target lesion in LAD or LCx (subject may be enrolled if only lesion is target lesion in RCA)

Angiographic Exclusion Criteria

• Phase 1: Target lesion TIMI flow <3

• Phase 2: Target lesion TIMI flow <2

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Cardiovascular Diseases

Intervention

Device:
• Percutaneous Coronary Intervention (PCI) TAXUS Petal
TAXUS Petal, paclitaxel eluting stent

Locations

Country	Name	City	State
France	Institut Hospitalier Jacques Cartier-ICPS, 6, Avenue du Noyer Lambert	Massy
Germany	HELIOS Klinikum Siegburg, Ringstrasse 49	Siegburg
New Zealand	Auckland City Hospital, Cardiac Investigations Unit, Park Road	Auckland	Grafton
New Zealand	Mercy Angiography Unit, 98 Mountain Road, First Floor	Auckland	Epsom

Sponsors (1)

Lead Sponsor	Collaborator
Boston Scientific Corporation

Countries where clinical trial is conducted

France,  Germany,  New Zealand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Composite safety endpoint at 30 days post-procedure: • All-cause mortality • Documented myocardial infarction • TVR		30 days	Yes
Secondary	Device Success Technical Success Clinical Procedural Success Device malfunctions Ease-of-Use parameters Clinical endpoints Main branch and side branch angiographic endpoints Main branch and side branch IVUS endpoints		Index procedure, 30 days, 6 months and 1 - 5 years	Yes